Chimeric Antigen-LgDNA Nanoparticles Attenuate Airway Th2 Polarization
Ruien Chen,Huamei Zou,Xiuwen Ye,Bailing Xie,Aizhi Zhang,Lihua Mo,Yu Liu,Huanping Zhang,Gui Yang,Pingchang Yang
DOI: https://doi.org/10.2147/ijn.s480722
IF: 7.033
2024-09-28
International Journal of Nanomedicine
Abstract:Ruien Chen, 1, * Huamei Zou, 1, * Xiuwen Ye, 1, * Bailing Xie, 2 Aizhi Zhang, 3 Lihua Mo, 4 Yu Liu, 4 Huanping Zhang, 5 Gui Yang, 1 Pingchang Yang 2 1 Department of Otolaryngology, Longgang Central Hospital and Guangzhou University of Chinese Traditional Medicine Shenzhen Clinical College, Shenzhen, 518116, People's Republic of China; 2 State Key Laboratory of Respiratory Diseases Allergy Division at Shenzhen University and Institute of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen, 518055, People's Republic of China; 3 Department of Critical Care Medicine, Second Hospital, Shanxi Medical University, Taiyuan, 030001, People's Republic of China; 4 Department of General Medicine Practice, Third Affiliated Hospital, Shenzhen University, Shenzhen, 518005, People's Republic of China; 5 Department of Allergy Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030001, People's Republic of China *These authors contributed equally to this work Correspondence: Pingchang Yang; Gui Yang, Email ; Introduction: The therapeutic efficacy for airway allergies needs to be improved. Th2 polarization is a primary pathological feature of airway allergies. We constructed chimeric antigen-LgDNA ( Lactobacillus rhamnosus DNA) nanoparticles (CAP-NPs). The effects of CAP-NPs on reconciling airway Th2 polarization were tested. Methods: In this study, disulfide bond-linked antigen-major histocompatibility complex II (MHC II)-LgDNA nanoparticles (NPs) were constructed and designated CAP-NPs. An airway Th2 polarization mouse model was established to test the effects of CAP-NPs on suppressing the Th2 response. Results: The CAP-NP components of ovalbumin (OVA), major histocompatibility complex II (MHC II), and LgDNA were confirmed in a series of laboratory tests. The CAP-NPs remained stable at pH7.2 for at least 96 h. In in vitro experiments, CAP-NPs bound to the surface of OVA-specific CD4 + T cells, which resulted in apoptosis of the antigen-specific CD4 + T cells. Removal of any of the three components from the NPs abolished the induction of apoptosis of antigen specific CD4 + T cells. CAP-NPs increased the expression of lysine-specific demethylase 5A (KDM5A) in CD4 + T cells. Histone H3K9 and the gene promoter of caspase 8 were demethylated by KDM5A, which led to transcription and expression of the caspase 8 gene. Administration of CAP-NPs significantly alleviated experimental airway Th2 polarization through activating the caspase 8-apoptosis signaling pathway. Discussion: In this paper, we constructed CAP-NPs that could induce antigen-specific CD4 + T cell apoptosis. Administration of CAP-NPs efficiently alleviated experimental airway Th2 polarization. Keywords: airway allergy, T cell, therapy, vaccine, nanoparticle Th2 polarization is a crucial factor associating with the pathogenesis of numerous immune disorders, such as allergic rhinitis, allergic asthma, allergic dermatitis, and certain autoimmune diseases. 1,2 Th2 polarization indicates that a large number of Th2 cells aggregate in the local tissues. Th2 cells produce higher than the required quantities of Th2 cytokines. 3 Th2 cytokines promote IgE production in plasma cells. Binding of IgE to the high-affinity IgE receptor (FcεRI) sensitizes mast cells. The release of allergic mediators, which triggers allergic attacks, occurs when sensitized mast cells are re-exposed to specific antigens. 4 The treatment of Th2 polarization-related diseases is not satisfactory currently. Most therapies are for the symptom control, such as anti-histamines and steroids. 5 Although the allergen specific immunotherapy is an etiology targeting remedy, its efficacy needs to be further improved. 6 Thus, there are only limited satisfactory therapies available for Th2 polarization currently. 7 Therefore, it is urgent to develop better therapies for Th2 polarization-related diseases. Referring to a published strategy, 8 we constructed a new type of nanoparticle containing the specific antigen ovalbumin (OVA), major histocompatibility complex II (MHC II), and LgDNA (DNA extracted from the probiotic strain Lactobacillus rhamnosus GG ). Specifically, this nanoparticle (NP) only has a peptide carrier to which the three substances are connected by disulfide bonds. This was designated as CAP-NP. Administration of CAP-NPs via nasal instillations effectively suppressed experimental Th2 p -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology